文献速递慢阻肺

老年慢阻肺患者处方大麻素使用与疾病负担和死亡率的关联

Morbidity and mortality associated with prescription cannabinoid drug use in COPD.
PubMed 文献 · Thorax · 2020-09-30

这项基于加拿大安大略省2006至2016年健康行政数据的回顾性队列研究,纳入66岁及以上慢阻肺患者,经倾向评分匹配后比较新使用处方口服合成大麻素(纳比隆、屈大麻酚)者与对照者的结局。结果显示,两组因慢阻肺或肺炎住院率无显著差异(HR 0.87;95%CI 0.61-1.24),但大麻素使用者全因死亡率显著更高(HR 1.64;95%CI 1.14-2.39);高剂量亚组住院(HR 2.78;95%CI 1.17-7.09)和死亡(HR 3.31;95%CI 1.30-9.51)风险均升高。

要点

  • 老年慢阻肺患者新使用处方大麻素与全因死亡率升高相关(HR 1.64)。
  • 高剂量大麻素亚组因慢阻肺或肺炎住院及死亡风险均显著增加。
  • 整体大麻素使用者因慢阻肺或肺炎住院率与对照无显著差异。

核心结论

  • 在老年慢阻肺患者中,新使用处方大麻素与不良结局发生率升高相关,尤其是全因死亡率。
  • 高剂量大麻素使用者的住院和死亡风险进一步增加,临床决策时应考虑这些观察结果。

研究设计与样本

  • 回顾性、基于人群的数据链接队列研究,分析加拿大安大略省2006至2016年健康行政数据。
  • 纳入66岁及以上、经高度特异性验证算法识别的慢阻肺患者,排除恶性肿瘤和接受姑息治疗者,排除后n=185 876。
  • 经倾向评分匹配,每组各2106例新使用大麻素者(定义为配发纳比隆或屈大麻酚且前一年未配发任一药物)和对照(新使用非大麻素药物者),匹配36个相关协变量,采用Cox比例风险回归。

主要发现

  • 新使用大麻素者与对照相比,因慢阻肺或肺炎住院率无显著差异(HR 0.87;95%CI 0.61-1.24)。
  • 新使用大麻素者全因死亡率显著高于对照(HR 1.64;95%CI 1.14-2.39)。
  • 接受较高剂量大麻素者相对对照,因慢阻肺和肺炎住院率升高(HR 2.78;95%CI 1.17-7.09),全因死亡率升高(HR 3.31;95%CI 1.30-9.51)。

临床怎么用

  • 对老年慢阻肺患者处方口服合成大麻素(纳比隆、屈大麻酚)时,应权衡全因死亡率升高的潜在风险。
  • 高剂量使用与大麻素相关的住院和死亡风险更高,应避免或谨慎使用高剂量。

局限性

  • 本研究为观察性设计,需进一步研究确认这些观察结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Respiratory-related morbidity and mortality were evaluated in relation to incident prescription oral synthetic cannabinoid (nabilone, dronabinol) use among older adults with chronic obstructive pulmonary disease (COPD). METHODS: This was a retrospective, population-based, data-linkage cohort study, analysing health administrative data from Ontario, Canada, from 2006 to 2016. We identified individuals aged 66 years and older with COPD, using a highly specific, validated algorithm, excluding individuals with malignancy and those receiving palliative care (n=185 876 after exclusions). An equivalent number (2106 in each group) of new cannabinoid users (defined as individuals dispensed either nabilone or dronabinol, with no dispensing for either drug in the year previous) and controls (defined as new users of a non-cannabinoid drug) were matched on 36 relevant covariates, using propensity scoring methods. Cox proportional hazard regression was used. RESULTS: Rate of hospitalisation for COPD or pneumonia was not significantly different between new cannabinoid users and controls (HR 0.87; 95% CI 0.61-1.24). However, significantly higher rates of all-cause mortality occurred among new cannabinoid users compared with controls (HR 1.64; 95% CI 1.14-2.39). Individuals receiving higher-dose cannabinoids relative to controls were observed to experience both increased rates of hospitalisation for COPD and pneumonia (HR 2.78; 95% CI 1.17-7.09) and all-cause mortality (HR 3.31; 95% CI 1.30-9.51). CONCLUSIONS: New cannabinoid use was associated with elevated rates of adverse outcomes among older adults with COPD. Although further research is needed to confirm these observations, our findings should be considered in decisions to use cannabinoids among older adults with COPD.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Vozoris NT, Pequeno P, Li P, et al. Morbidity and mortality associated with prescription cannabinoid drug use in COPD. Thorax. 2020. PMID: 32999059. doi:10.1136/thoraxjnl-2020-215346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。